← Back to Search

Vaccine

V116 Vaccine for Pneumococcal Disease (STRIDE-8 Trial)

Phase 3
Waitlist Available
Research Sponsored by Merck Sharp & Dohme LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has documented result(s) of ≥1 of the following risk conditions for pneumococcal disease: diabetes mellitus, receiving treatment with ≥1 approved antidiabetic medication, with all Hemoglobin A1c (HbA1c) measurements ≤9% within 6 months before first study vaccination; compensated chronic liver disease; diagnosis of chronic obstructive pulmonary disease (COPD) managed per local guidelines; diagnosis of mild or moderate persistent asthma managed per local guidelines; confirmed diagnosis of chronic heart disease managed per local guidelines; confirmed diagnosis of chronic kidney disease (>3 months duration).
Be between 18 and 65 years old
Must not have
Has a history of active hepatitis.
Has a history of diabetic ketoacidosis or 2 or more episodes of severe, symptomatic hypoglycemia within 3 months before first study vaccination (Day 1).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to month 6
Awards & highlights
Pivotal Trial

Summary

This trial is testing a new vaccine (V116) that protects against 21 types of bacteria causing pneumonia. It targets adults at risk of these infections and works by training the immune system to fight these bacteria.

Who is the study for?
Adults at high risk for pneumococcal disease, stable on current treatments with conditions like diabetes (with controlled HbA1c), chronic liver disease, COPD, asthma, heart or kidney disease. Must not be pregnant or planning to get pregnant and agree to use contraception if of childbearing potential. Excludes those with recent severe infections, hypersensitivity to vaccine components, bleeding disorders preventing shots, active cancer treatment within 3 years, planned major surgery or organ transplant during the study.
What is being tested?
The trial is testing a new vaccine called V116 against pneumococcal diseases compared to an existing vaccine regimen including PCV15 and PPSV23. It aims to assess safety and immune response by measuring how well the body can fight off the bacteria after vaccination.
What are the potential side effects?
Possible side effects include reactions at the injection site such as pain and swelling, feverish symptoms similar to mild flu-like illness. There may also be allergic reactions in rare cases due to sensitivity towards any component of the vaccines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a condition like diabetes, liver disease, COPD, asthma, heart or kidney disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had active hepatitis in the past.
Select...
I have had diabetic ketoacidosis or two severe low blood sugar episodes recently.
Select...
I have not had a heart attack or stroke in the last 3 months.
Select...
I have severe lung blood pressure or Eisenmenger syndrome.
Select...
I have a history of chronic kidney issues or autoimmune kidney disease.
Select...
I had a serious lung infection confirmed by a lab test in the last 3 years.
Select...
I have a blood clotting disorder that prevents me from getting shots in my muscles.
Select...
I am scheduled for a major organ transplant or surgery during this study.
Select...
I have had or will have a pneumococcal vaccine outside this study's protocol.
Select...
I am currently on medication that affects my immune system.
Select...
I haven't had a live virus vaccine in the last 30 days and won't have one for 30 days after getting the study vaccine.
Select...
I use oxygen at home regularly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Participants with solicited injection-site adverse events (AEs) from Day 1 through Day 5 post-vaccination
Participants with solicited systemic AEs from Day 1 through Day 5 post-vaccination
Participants with vaccine-related serious adverse events (SAEs) from Day 1 through the duration of participation in the study
+1 more
Secondary study objectives
Serotype-specific GMFRs from baseline to post-vaccination with V116 and PCV15 + PPSV2 for Immunoglobulin G (IgG) responses
Serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) post-vaccination
Serotype-specific geometric mean fold rises (GMFRs) from baseline to post-vaccination with V116 and PCV15 + PPSV2 for OPA responses
+2 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: V116Experimental Treatment2 Interventions
Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo for PCV15 + PPSV23 on Week 8
Group II: PCV15 + PPSV23Active Control2 Interventions
Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
V116
2022
Completed Phase 3
~8610
Placebo for PCV15 + PPSV23
2023
Completed Phase 3
~520

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Pneumococcal Disease involve the use of pneumococcal conjugate vaccines (e.g., PCV13, PCV15, and the investigational V116). These vaccines work by stimulating the immune system to produce specific antibodies that enhance opsonophagocytic activity, a process where antibodies mark the bacteria for destruction by immune cells. This mechanism is vital for Pneumococcal Disease patients as it helps prevent severe infections by enabling the immune system to recognize and eliminate the bacteria more effectively, thereby reducing morbidity and mortality associated with the disease.
Pneumococcal immunization in immunocompromised hosts: where do we stand?

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor
3,978 Previous Clinical Trials
5,177,511 Total Patients Enrolled
Clinical DirectorStudy DirectorMerck Sharp & Dohme LLC
18 Previous Clinical Trials
4,278 Total Patients Enrolled

Media Library

V116 (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05696080 — Phase 3
Pneumococcal Disease Research Study Groups: V116, PCV15 + PPSV23
Pneumococcal Disease Clinical Trial 2023: V116 Highlights & Side Effects. Trial Name: NCT05696080 — Phase 3
V116 (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05696080 — Phase 3
~194 spots leftby Oct 2025